ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
3 announcements with these filters
Sanjivani Paranteral Q1 FY27 consolidated revenue grew 33.8% YoY to ₹238.4 Mn, driven by the new Pune IV-fluid plant ramp-up. Transitioning to a multi-vertical platform with injectables, orals, and nutraceuticals.
Sanjivani Paranteral Q4 FY26 earnings transcript. Management transitions to a multi-vertical platform with base formulation business and new IVF and nutraceutical ventures.
Sanjivani Paranteral's Q4 & FY26 presentation shows significant decline in standalone financials. Focus remains on injectables (53.5% FY26 revenue) and export markets (78.5% FY26 revenue).